Based on this large phase III trial, the current recommendations from the National Comprehensive Cancer Network, Inc. (NCCN) include cetuximab/vinorelbine/cisplatin as a first-line therapy option in patients who meet criteria for therapy with cetuximab (i.e. NSCLC IIIB with a pleural effusion or stage IV, EGFR expression by immunohistochemistry [≥ 1 positive tumor cell], age ≥ 18, ECOG PS 0–2, no known brain metastasis and no prior chemotherapy or anti-EGFR therapy) [35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.